Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription 02.06.2025 1 AJR Am J Roentgenol 1 Am J Clin Pathol 1 Ann Oncol 5 Anticancer Res 6 BMC Cancer 4 Breast Cancer 1 Breast Cancer (Auckl) 2 Breast Cancer (Dove Med Press) 3 Breast Cancer Res 5 Breast Cancer Res Treat 2 Breast J 1 Cancer 1 Cancer Lett 1 Cancer Res 9 Clin Breast Cancer 1 Clin Exp Metastasis 4 Eur J Surg Oncol 1 Eur Radiol 1 Exp Cell Res 1 Int J Oncol 1 Int J Radiat Oncol Biol Phys 2 J Biol Chem 1 J Nucl Med 1 J Surg Oncol 2 Lancet 2 Mod Pathol 1 Nat Rev Clin Oncol 2 NPJ Breast Cancer 1 Oncol Rep 1 PLoS Comput Biol 2 PLoS One 1 Radiologia (Engl Ed) 1 Radiology 1 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. TAKAHASHI T
   The Natural History of Screen-Detected Prostate and Breast Cancer.
   AJR Am J Roentgenol. 2025 May 28. doi: 10.2214/AJR.25.33170.
   PubMed        
   
   

   
   Am J Clin Pathol

2. TSENG YA, Tamayo S, Abada E, Marketkar S, et al
   Interobserver agreement in scoring HER2-negative and HER2-low immunohistochemistry in breast cancer: Reasons for discordance and impact of a single training session.
   Am J Clin Pathol. 2025 May 23:aqaf043. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Ann Oncol

3. LIU Y, Zhang C, Liu Y
   Letter to the editor 'A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases' by F. Andre et al.
   Ann Oncol. 2025 May 21:S0923-7534(25)00735-5. doi: 10.1016/j.annonc.2025.
   PubMed        
   
   

   
   Anticancer Res

4. IORIO V, Delia P, Solazzo AP, Fazio I, et al
   Phase II Study of the Effectiveness of the Germinated Wheat-derived Rigenase Plus Polyhexanide in the Prophylaxis for Hypofractionated Radiation-induced Acute Skin Toxicity in Breast Cancer.
   Anticancer Res. 2025;45:2539-2550.
   PubMed         Abstract available
   
   
5. KIM HG, Kang SY, Kim KM, Kim JY, et al
   Combined Biomarkers for Prediction of Immune Checkpoint Inhibitor Response in Patients With Triple-negative Breast Cancer.
   Anticancer Res. 2025;45:2575-2586.
   PubMed         Abstract available
   
   
6. HONG SD, Kang MS, Katuwal NB, Ghosh M, et al
   Intratumoral Injection of Allogeneic NK Cell With Chemotherapy in a Triple-negative Breast Cancer Preclinical Model.
   Anticancer Res. 2025;45:2669-2688.
   PubMed         Abstract available
   
   
7. LEE IH, Kim EA, Lee SJ, Kang B, et al
   The Role of EMP2 in Triple-negative Breast Cancer.
   Anticancer Res. 2025;45:2417-2427.
   PubMed         Abstract available
   
   
8. KOKKONEN K, Utriainen M, Penttinen H, Vehmanen L, et al
   Feasibility of an Exercise Training Program Among Patients With Newly Diagnosed Advanced Breast Cancer.
   Anticancer Res. 2025;45:2605-2618.
   PubMed         Abstract available
   
   

   
   BMC Cancer

9. RAJABPOUR MV, Seyyedsalehi MS, Nahvijou A, Nemati S, et al
   Evaluating the breast cancer quality of care indicators in Iran; multicenter study.
   BMC Cancer. 2025;25:925.
   PubMed         Abstract available
   
   
10. HE C, Yu T, Yang L, He L, et al
    Clinical prediction of pathological complete response in breast cancer: a machine learning study.
    BMC Cancer. 2025;25:933.
    PubMed         Abstract available
    
    
11. NOPOUR R
    Prediction of one-year recurrence among breast cancer patients undergone surgery using artificial intelligence-based algorithms: a retrospective study on prognostic factors.
    BMC Cancer. 2025;25:940.
    PubMed         Abstract available
    
    
12. SCHANTZ C, Gnangnon FHR, Aboubakar M, Agbodande AK, et al
    Barriers and opportunities related to access to oncology care in Benin: a qualitative study on breast cancer.
    BMC Cancer. 2025;25:947.
    PubMed         Abstract available
    
    
13. YANG B, Sun Z, Ouyang Q, Tong Z, et al
    Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China.
    BMC Cancer. 2025;25:951.
    PubMed         Abstract available
    
    
14. WANG C, Chen J, Lv X, Yun T, et al
    Ki-67-Playing a key role in breast cancer but difficult to apply precisely in the real world.
    BMC Cancer. 2025;25:962.
    PubMed         Abstract available
    
    

    
    Breast Cancer

15. ISOGAI A, Terada M, Wanifuchi-Endo Y, Fujita T, et al
    Optimal patient population for adjuvant S-1 therapy in hormone receptor-positive, HER2-negative early breast cancer.
    Breast Cancer. 2025 May 24. doi: 10.1007/s12282-025-01722.
    PubMed         Abstract available
    
    
16. COOPER J, Airstone B, Beaman E, Carollo E, et al
    Helix pomatia agglutinin bound to surface glycans of small extracellular vesicles in-vitro and in-vivo increases in early and late stage breast cancer.
    Breast Cancer. 2025 May 24. doi: 10.1007/s12282-025-01724.
    PubMed         Abstract available
    
    
17. IMOTO S, Yasojima H, Nagashima T, Onishi T, et al
    Axillary surgery in patients with breast cancer with one to three positive micro- or macrometastases in the sentinel lymph nodes: an observational study.
    Breast Cancer. 2025 May 25. doi: 10.1007/s12282-025-01726.
    PubMed         Abstract available
    
    
18. SHIEN T, Nogi H, Ogiya A, Ishitobi M, et al
    Immediate breast reconstruction surgery for breast cancer: current status and future directions.
    Breast Cancer. 2025 May 26. doi: 10.1007/s12282-025-01723.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Auckl)

19. VALENCIA G, Rioja P, Peralta O, Chirito M, et al
    Real-World Experience of HER2-Positive Advanced Breast Cancer (ABC) Treatment and Evaluation of Blood Biomarkers in a Public Institution in Latin America (LATAM).
    Breast Cancer (Auckl). 2025;19:11782234251342477.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

20. ELAMIN HES, Elamin HES, Abd El-Raheem GOH, Noma M, et al
    Barriers to Early Breast Cancer Diagnosis in Sudanese Women Before the War.
    Breast Cancer (Dove Med Press). 2025;17:433-445.
    PubMed         Abstract available
    
    
21. RAO B, Huo P, Lu J, Huang W, et al
    Advances in Targeted Therapy for Brain Metastases in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer: A Focus on ADCs and TKIs.
    Breast Cancer (Dove Med Press). 2025;17:423-432.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

22. ROY R, Schunkert EM, Olivova P, Gilar M, et al
    Identification of vitronectin as a potential non-invasive biomarker of metastatic breast cancer using a label-free LC-MS/MS approach.
    Breast Cancer Res. 2025;27:94.
    PubMed         Abstract available
    
    
23. XUAN W, Li W, Ke L, Shen Y, et al
    Investigating the mechanism of inositol against paclitaxel chemoresistance on triple-negative breast cancer by using 7T multiparametric MRI and mitochondrial changes.
    Breast Cancer Res. 2025;27:93.
    PubMed         Abstract available
    
    
24. GAO Y, Zuo L, Zheng Y, Sun K, et al
    NOTCH1 inhibition enhances immunogenicity and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.
    Breast Cancer Res. 2025;27:92.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

25. SIREK A, Sirek T, Nowakowski R, Borawski P, et al
    Subtype-specific dysregulation of biogenic amine-related genes and miRNAs in breast cancer: identification of DRD2, HRH2, and HRH4 as potential therapeutic targets in TNBC and HER2+ subtypes.
    Breast Cancer Res Treat. 2025 May 27. doi: 10.1007/s10549-025-07732.
    PubMed         Abstract available
    
    
26. FREITAS AJA, Causin RL, Calfa S, Santana IVV, et al
    Exploring the Nottingham classification: assessing gene expression profiles in breast cancer patients and their association with outcomes.
    Breast Cancer Res Treat. 2025 May 28. doi: 10.1007/s10549-025-07718.
    PubMed         Abstract available
    
    
27. SPRIET J, Miled AB, Mailliez A, Bonnier S, et al
    Breast magnetic resonance imaging patterns of tumor regression after neoadjuvant chemotherapy and immunotherapy in early triple-negative breast cancer patients: prediction of pathological response and performance of ultrafast sequences.
    Breast Cancer Res Treat. 2025 May 28. doi: 10.1007/s10549-025-07650.
    PubMed         Abstract available
    
    
28. GEMMILL JAL, Thompson P, Batiste R, Vacchi-Suzzi C, et al
    Metastatic breast cancer through the Oncotype DX Breast Recurrence Score(R): insights from a small cohort study.
    Breast Cancer Res Treat. 2025 May 28. doi: 10.1007/s10549-025-07736.
    PubMed         Abstract available
    
    
29. MEDFORD AJ, Velimirovic M, Gefen Y, Niemierko A, et al
    Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes.
    Breast Cancer Res Treat. 2025 May 29. doi: 10.1007/s10549-025-07710.
    PubMed         Abstract available
    
    

    
    Breast J

30. GORODETSKA I, Samusieva A, Lahuta T, Ponomarova O, et al
    Exploring New Frontiers: Alternative Breast Cancer Treatments Through Glycocalyx Research.
    Breast J. 2025;2025:9952727.
    PubMed         Abstract available
    
    
31. MAEDA Y, Sato A, Matsumoto A, Ikeda T, et al
    Efficacy of Presurgical Short-Term Endocrine Therapy During the Waiting Period for Surgery in Postmenopausal Hormone Receptor-Positive Breast Cancer.
    Breast J. 2025;2025:9976413.
    PubMed         Abstract available
    
    

    
    Cancer

32. WANIS KN, Mitchell MP, Giordano SH, Litton JK, et al
    Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers.
    Cancer. 2025;131:e35910.
    PubMed         Abstract available
    
    

    
    Cancer Lett

33. WU R, Yu S, Bi A, Li Y, et al
    Therapeutic targeting of circTNK2 with nanoparticles restores tamoxifen sensitivity and enhances NK cell-mediated immunity in ER-positive breast cancer.
    Cancer Lett. 2025 May 24:217823. doi: 10.1016/j.canlet.2025.217823.
    PubMed         Abstract available
    
    

    
    Cancer Res

34. KIM EJ, Wang Y, Chen YL, Ma M, et al
    CARM1-mediated MAP2K4 methylation potentiates the oncogenic functions of MAP2K4 and constitutes a targetable dependency in triple-negative breast cancer.
    Cancer Res. 2025 May 29. doi: 10.1158/0008-5472.CAN-24-3476.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

35. BRUNETTI N, Campi C, Piana M, Picone I, et al
    A Radiomic and Clinical Data-Based Risk Model for Malignancy Prediction of Breast BI-RADS 4A Microcalcifications.
    Clin Breast Cancer. 2025;25:e461-e469.
    PubMed         Abstract available
    
    
36. MARCADET J, Bouche C, Arellano C, Gauroy E, et al
    Is Immediate Breast Reconstruction an Option for Elderly Women? A Comparative Study Between Elderly and Younger Population.
    Clin Breast Cancer. 2025;25:e440-e449.
    PubMed         Abstract available
    
    
37. WU CH, Chang MH, Chen HJ, Tsai HH, et al
    Artificial Intelligence-Based Automatic Mitosis Scoring in Breast Cancer Improves Inter-Observer Concordance and Efficiency.
    Clin Breast Cancer. 2025 May 1:S1526-8209(25)00112.
    PubMed         Abstract available
    
    
38. QUINN RM, Bernal AM, Oh SY, Anampa JD, et al
    Trends in Incidence of Invasive Lobular Carcinoma of the Breast by Race: Patterns by Age, Cancer Stage, and Socioeconomic Factors in the United States, 1992-2019.
    Clin Breast Cancer. 2025;25:e394-e402.
    PubMed         Abstract available
    
    
39. KIM JJ, Kim JY, Hwangbo L, Lee H, et al
    Computer-Aided Diagnosis of ER-positive, HER2-Negative Breast Cancer on Dynamic Contrast-Enhanced MRI: Associations With Oncotype DX Recurrence Scores.
    Clin Breast Cancer. 2025 Apr 29:S1526-8209(25)00105.
    PubMed         Abstract available
    
    
40. PAIVA CE, Guimaraes VS, Silva ATF, Maia YCP, et al
    Navigating Endocrine Sensitivity Assessment in Nonmetastatic Breast Cancer Through Early On-Treatment Ki67 Understanding.
    Clin Breast Cancer. 2025 Apr 30:S1526-8209(25)00111.
    PubMed         Abstract available
    
    
41. LI Y, Sundquist K, Wang X, Sundquist J, et al
    The Mitochondrial Signature for Predicting Outcome of Early-Stage Breast Cancer by Machine Learning.
    Clin Breast Cancer. 2025 May 3:S1526-8209(25)00110.
    PubMed         Abstract available
    
    
42. MATUSZ-FISHER A, Chen A, Donahue EE, Schepel CR, et al
    Clinical outcomes by histologic pattern of early-stage metaplastic breast cancer: A single-institution retrospective study.
    Clin Breast Cancer. 2025 May 3:S1526-8209(25)00113.
    PubMed         Abstract available
    
    
43. VELLAN CJ, Natesan V, Jayapalan JJ
    Metabolomics Biomarkers for Breast Cancer: An updated perspective.
    Clin Breast Cancer. 2025 May 8:S1526-8209(25)00118.
    PubMed         Abstract available
    
    

    
    Clin Exp Metastasis

44. RUSSANO F, Corrado G, Bonadies A, Migliano E, et al
    Prospective multicentre study of patients with cutaneous metastases from breast cancer treated with electrochemotherapy.
    Clin Exp Metastasis. 2025;42:32.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

45. MATILAINEN S, Liikanen H, Lassila R, Laitinen MK, et al
    Assessing the diagnostic value of oncological biomarkers for identifying primary malignancies in skeletal metastatic disease.
    Eur J Surg Oncol. 2025;51:109688.
    PubMed         Abstract available
    
    
46. BOLAND MR, Pantiora E, Rutherford C, Evoy D, et al
    Use of superparamagnetic iron oxide for sentinel lymph node detection following neoadjuvant systemic therapy. A systematic review and meta-analysis.
    Eur J Surg Oncol. 2025;51:109684.
    PubMed         Abstract available
    
    
47. PERADZE N, Polizzi A, Pagan E, Bottazzoli E, et al
    Invasive Pleomorphic Lobular Carcinoma of the breast: Clinicopathological features, treatment patterns and outcomes.
    Eur J Surg Oncol. 2025;51:109714.
    PubMed         Abstract available
    
    
48. SONI A, Morgan J, Wyld L
    A qualitative study exploring the views of global healthcare professionals towards de-escalation of axillary surgery in early breast cancer.
    Eur J Surg Oncol. 2025;51:110079.
    PubMed         Abstract available
    
    

    
    Eur Radiol

49. VERBOOM SD, Mainprize JG, Peters J, Broeders M, et al
    More than density: validating a mammographic masking prediction model in Dutch breast cancer screening.
    Eur Radiol. 2025 May 29. doi: 10.1007/s00330-025-11687.
    PubMed         Abstract available
    
    

    
    Exp Cell Res

50. SUN X, Zang H, Li S, Kong J, et al
    EFHD1 promotes breast cancer progression through estrogen signaling.
    Exp Cell Res. 2025 May 27:114620. doi: 10.1016/j.yexcr.2025.114620.
    PubMed         Abstract available
    
    

    
    Int J Oncol

51. KIM ES
    Molecular targets and therapies associated with poor prognosis of triple?negative breast cancer (Review).
    Int J Oncol. 2025;66:52.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

52. HONG SW, Kim EK, Shin HC, Beom J, et al
    Relationship of Immediate Breast Reconstruction and the Development of Lymphedema in Breast Cancer Patients with Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2025 May 25:S0360-3016(25)00531.
    PubMed         Abstract available
    
    

    
    J Biol Chem

53. HANG Q, Li W, Guo J, Zuo S, et al
    Inhibitory effects of beta-galactoside alpha2,6-sialyltransferase 1 on the Hippo pathway in breast cancer cells.
    J Biol Chem. 2025 May 21:110266. doi: 10.1016/j.jbc.2025.110266.
    PubMed         Abstract available
    
    
54. QIU Y, Luan G, Liu Y, He Y, et al
    The transcriptional regulator Sin3a activates CD44 and promotes collective luminal breast cancer cell migration.
    J Biol Chem. 2025 May 21:110264. doi: 10.1016/j.jbc.2025.110264.
    PubMed         Abstract available
    
    

    
    J Nucl Med

55. LYNCH SE, Crawford C, Hunt AL, Sligh LL, et al
    Granzyme B PET Imaging Predicts Response to Immunotherapy in a Diet-Induced Obesity Model of Breast Cancer.
    J Nucl Med. 2025 May 29:jnumed.124.268938. doi: 10.2967/jnumed.124.268938.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

56. DAVE N, Hajj JP, Ahmed S, Hulsman L, et al
    Immediate Breast Reconstruction for Inflammatory Breast Carcinoma: A Scoping Review.
    J Surg Oncol. 2025;131:775-781.
    PubMed         Abstract available
    
    

    
    Lancet

57. HOUSSAMI N
    Breast cancer screening at a crossroads: supplemental imaging for dense breasts.
    Lancet. 2025 May 21:S0140-6736(25)00803-7. doi: 10.1016/S0140-6736(25)00803.
    PubMed        
    
    
58. GILBERT FJ, Payne NR, Allajbeu I, Yit L, et al
    Comparison of supplemental breast cancer imaging techniques-interim results from the BRAID randomised controlled trial.
    Lancet. 2025 May 21:S0140-6736(25)00582-3. doi: 10.1016/S0140-6736(25)00582.
    PubMed         Abstract available
    
    

    
    Mod Pathol

59. HAN R, Pareja F, Ross DS, Grabenstetter A, et al
    Frank Invasion in Tall Cell Carcinoma With Reversed Polarity of the Breast: Report of Two Cases.
    Mod Pathol. 2025;38:100714.
    PubMed         Abstract available
    
    
60. RAKHA EA, Quinn C, Raymond W, Allison KH, et al
    Classification of Fibroepithelial Lesions of the Breast in Core Needle Biopsy With Implications for Further Management.
    Mod Pathol. 2025;38:100734.
    PubMed         Abstract available
    
    

    
    Nat Rev Clin Oncol

61. ROBBINS CJ, Bates KM, Rimm DL
    HER2 testing: evolution and update for a companion diagnostic assay.
    Nat Rev Clin Oncol. 2025;22:408-423.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

62. YEH C, Han R, Kulkarni A, White C, et al
    Treatment patterns and clinical outcomes of patients with HER2-positive T1micN0 breast cancer: a single-center analysis.
    NPJ Breast Cancer. 2025;11:47.
    PubMed         Abstract available
    
    
63. VAN GEEL JJL, Jongbloed EM, Moustaquim J, van der Schoor G, et al
    Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study.
    NPJ Breast Cancer. 2025;11:48.
    PubMed         Abstract available
    
    

    
    Oncol Rep

64. ZUO X, Qin Y, Zhang X, Ning Q, et al
    [Retracted] Breast cancer cells are arrested at different phases of the cell cycle following the re?expression of ARHI.
    Oncol Rep. 2025;54:83.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

65. HOPFL S, Ozverin M, Nowack H, Tamas R, et al
    Integrated mathematical and experimental modeling uncovers enhanced EMT plasticity upon loss of the DLC1 tumor suppressor.
    PLoS Comput Biol. 2025;21:e1013076.
    PubMed         Abstract available
    
    

    
    PLoS One

66. KHODADADI H, Nazem S
    Improving cancer detection through computer-aided diagnosis: A comprehensive analysis of nonlinear and texture features in breast thermograms.
    PLoS One. 2025;20:e0322934.
    PubMed         Abstract available
    
    
67. ABUBAKARI AK, Gross J, Adusei-Poku E
    Factors influencing clinical breast cancer screening: A cross-sectional study among Islamic women in Kumasi Metropolis of Ghana.
    PLoS One. 2025;20:e0320726.
    PubMed         Abstract available
    
    

    
    Radiologia (Engl Ed)

68. FRESNO VALLESPIR M, Vazquez de Las Heras I, Gasior D, Morales Rosa A, et al
    Radiological findings of adenoid cystic carcinoma of the breast.
    Radiologia (Engl Ed). 2025;67:378-383.
    PubMed         Abstract available
    
    

    
    Radiology

69. BECHYNA S, Baltzer PAT
    Impact of Background Parenchymal Enhancement on Diagnostic Performance of Breast MRI: A Systematic Review and Meta-Analysis.
    Radiology. 2025;315:e241919.
    PubMed         Abstract available
    
    

    
    Radiother Oncol

70. PRADES-SAGARRA E, Geurts FAP, Biemans R, Lieuwes NG, et al
    The radiosensitizing effect of Caffeic Acid Phenethyl Ester in breast cancer is dependent on p53 status.
    Radiother Oncol. 2025;209:110945.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.